Copyright
©The Author(s) 2020.
World J Gastrointest Surg. Sep 27, 2020; 12(9): 377-389
Published online Sep 27, 2020. doi: 10.4240/wjgs.v12.i9.377
Published online Sep 27, 2020. doi: 10.4240/wjgs.v12.i9.377
Table 2 Baseline characteristics of patients with advanced esophageal cancer who refused chemotherapy with and without receiving palliative treatment, n (%)
| Variable | All patients (n = 1493) | No chemotherapy/received palliative therapy (n = 407) | No chemotherapy/no palliative therapy (n = 1086) | P value | |
| Age (yr) | 0.775 | ||||
| Median (IQR) | 70 (62-79) | 71 (62-79) | 70 (62-79) | ||
| Gender | 0.748 | ||||
| Female | 340 (22.77) | 95 (23.34) | 245 (22.56) | ||
| Male | 1153 (77.23) | 312 (76.66) | 841 (77.44) | ||
| Race1 | 0.727 | ||||
| Black | 142 (9.50) | 38 (9.36) | 104 (9.58) | ||
| Other | 82 (5.46) | 19 (4.71) | 62 (5.71) | ||
| White | 1270 (85.04) | 350 (85.93) | 920 (84.71) | ||
| Insurance type1 | 0.398 | ||||
| Medicaid | 134 (8.98) | 33 (8.11) | 101 (9.30) | ||
| Medicare | 944 (63.30) | 255 (62.65) | 689 (63.45) | ||
| Not insured | 89 (5.96) | 19 (4.67) | 70 (6.44) | ||
| Other government | 21 (1.41) | 7 (1.72) | 14 (1.29) | ||
| Private | 305 (20.43) | 93 (22.85) | 212 (19.52) | ||
| Income quartiles for place of residence1 | 0.282 | ||||
| Less than $30000 | 236 (15.79) | 70 (17.20) | 166 (15.29) | ||
| $30000-$34999 | 291 (19.51) | 87 (21.38) | 204 (18.78) | ||
| $35000-$45999 | 452 (30.29) | 125 (30.71) | 327 (30.11) | ||
| $46000+ | 514 (34.41) | 125 (30.71) | 389 (35.82) | ||
| Education level1,2 | 0.971 | ||||
| Less than 14% | 489 (32.73) | 134 (32.92) | 355 (32.69) | ||
| 14%-19.9% | 372 (24.94) | 101 (24.82) | 271 (24.95) | ||
| 20%-28.9% | 369 (24.73) | 97 (23.83) | 272 (25.05) | ||
| 29% or more | 263 (17.60) | 75 (18.43) | 188 (17.31) | ||
| Treatment site1 | 0.118 | ||||
| Academic | 554 (37.11) | 164 (40.29) | 390 (35.91) | ||
| Non-Academic | 939 (62.89) | 243 (59.71) | 696 (64.09) | ||
| Geographic location in United States1 | 0.003 | ||||
| Midwest | 487 (32.62) | 128 (31.45) | 359 (33.05) | ||
| Northeast | 341 (22.84) | 116 (28.50) | 225 (20.72) | ||
| South | 431 (28.87) | 96 (23.59) | 335 (30.85) | ||
| West | 234 (15.67) | 67 (16.46) | 167 (15.38) | ||
| Residence area type1 | 0.637 | ||||
| Metro | 1183 (79.25) | 316 (77.61) | 867 (79.83) | ||
| Rural | 31 (2.07) | 9 (2.28) | 22 (2.02) | ||
| Urban | 279 (18.68) | 82 (20.11) | 197 (18.15) | ||
| Number of comorbidities3 | 0.759 | ||||
| 0 | 990 (66.31) | 266 (65.36) | 724 (66.67) | ||
| 1 | 351 (23.51) | 101 (24.82) | 250 (23.02) | ||
| ≥ 2 | 152 (10.18) | 40 (9.83) | 112 (10.31) | ||
| Year of diagnosis | 0.753 | ||||
| 2004-2009 | 604 (40.46) | 162 (39.8) | 442 (40.7) | ||
| 2010-2014 | 889 (59.54) | 245 (60.2) | 644 (59.3) | ||
| Grade1,4 | 0.395 | ||||
| 1 | 50 (3.35) | 16 (3.93) | 34 (3.13) | ||
| 2 | 513 (34.36) | 127 (31.20) | 386 (35.54) | ||
| 3 | 901 (60.35) | 254 (62.41) | 647 (59.58) | ||
| 4 | 29 (1.94) | 10 (2.46) | 19 (1.75) | ||
| AJCC T stage1 | 0.091 | ||||
| T0 | 17 (1.14) | 3 (0.74) | 14 (1.29) | ||
| T1 | 335 (22.44) | 80 (19.65) | 255 (23.48) | ||
| T2 | 162 (10.85) | 37 (9.09) | 125 (11.51) | ||
| T3 | 499 (33.42) | 160 (39.31) | 339 (31.21) | ||
| T4 | 480 (32.20) | 127 (31.20) | 353 (32.50) | ||
| AJCC N stage1 | 0.006 | ||||
| Positive | 1083 (72.54) | 319 (78.38) | 764 (70.35) | ||
| Negative | 410 (27.46) | 88 (21.62) | 322 (29.65) | ||
- Citation: Kim S, DiPeri TP, Guan M, Placencio-Hickok VR, Kim H, Liu JY, Hendifar A, Klempner SJ, Nipp R, Gangi A, Burch M, Waters K, Cho M, Chao J, Atkins K, Kamrava M, Tuli R, Gong J. Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. World J Gastrointest Surg 2020; 12(9): 377-389
- URL: https://www.wjgnet.com/1948-9366/full/v12/i9/377.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v12.i9.377